Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26504007 | 0.89 | PLA2G1B (0.34) | PLA2G1BPLA2G2AALDH1A1 | |
| SCHEMBL20076527 | 0.82 | CYP1A2 (0.39) | PLA2G1BPLA2G2AALDH1A1OPRM1OPRD1 | |
| SCHEMBL436979 | 0.82 | PLA2G1B (0.39) | PLA2G1BPLA2G2AALDH1A1OPRM1OPRD1 | |
| SCHEMBL3409861 | 0.82 | PLA2G1B (0.39) | PLA2G1BPLA2G2AALDH1A1OPRM1OPRD1 | |
| SCHEMBL13106842 | 0.80 | PLA2G1B (0.35) | PLA2G1BPLA2G2A | |
| SCHEMBL5948663 | 0.79 | PLA2G1B (0.36) | PLA2G1BPLA2G2A | |
| SCHEMBL5949196 | 0.79 | PLA2G1B (0.31) | PLA2G1BPLA2G2A | |
| SCHEMBL19258143 | 0.77 | ALDH1A1 (0.36) | PLA2G1BPLA2G2AALDH1A1OPRM1OPRD1 | |
| SCHEMBL26510941 | 0.77 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL27306915 | 0.77 | PLA2G1B (0.32) | PLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100775-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210100775-A1 | COMBINATION THERAPIES | DDIT3, MCL1, ERCC2 | PLA2G1B 3764/4885PLA2G2A 3337/4885ALDH1A1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.